Integration of Rous sarcoma virus DNA: A CA dinucleotide is not required for integration of the U3 end of viral DNA

Journal of Virology

Volumn 82, Issue 22, 2008, Pages 11480-11483

  Oh, Jangsuk ^a,b   Chang, Kevin W ^b,c   Hughes, Stephen H ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; NUCLEOTIDE; RIBONUCLEASE H; VIRUS DNA;

ARTICLE; DNA SEQUENCE; ENZYME SUBSTRATE; GENE DELETION; GENE INSERTION; IN VIVO GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; ROUS SARCOMA ONCOVIRUS; VIRUS MUTANT; ENZYME SPECIFICITY; GENETICS; METABOLISM; PHYSIOLOGY; VIRUS DNA CELL DNA INTERACTION;

RICE STRIPE VIRUS; ROUS SARCOMA VIRUS;

DNA, VIRAL; INTEGRASES; ROUS SARCOMA VIRUS; SUBSTRATE SPECIFICITY; VIRUS INTEGRATION;

EID: 55549094449     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01353-08     Document Type: Article

References (24)

1. Balakrishnan, M., and C. B. Jonsson. 1997. Functional identification of nucleotides conferring substrate specificity to retroviral integrase reactions. J. Virol. 71:1025-1035.
2. Bushman, F. D., and R. Craigie. 1991. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 88:1339-1343.
3. Chang, K. W., J. G. Julias, W. G. Alvord, J. Oh, and S. H. Hughes. 2005. Alternate polypurine tracts (PPTs) affect the Rous sarcoma virus RNase H cleavage specificity and reveal a preferential cleavage following a GA dinucleotide sequence at the PPT-U3 junction. J. Virol. 79:13694-13704.
4. Chang, K. W., J. Oh, W. G. Alvord, and S. H. Hughes. 2008. The effects of alternate polypurine tracts (PPTs) and mutations of sequences adjacent to the PPT on viral replication and cleavage specificity of Rous sarcoma virus reverse transcriptase. J. Virol. 82:8592-8604.
5. Chiu, R., and D. P. Grandgenett. 2003. Molecular and genetic determinanats of Rous sarcoma virus integrase for concerted DNA integration. J. Virol. 77:6482-6492.
6. Craigie, R., T. Fujiwara, and F. Bushman. 1990. The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell 62:829-837.
7. Dash, C. J., W. Rausch, and S. F. Le Grice. 2004. Using pyrrolo-deoxycytosine to probe RNA/DNA hybrids containing the human immunodeficiency virus type-1 3′ polypurine tract. Nucleic Acids Res. 32:1539-1547.
8. Fujiwara, T., and R. Craigie. 1989. Integration of mini-retroviral DNA: a cell-free reaction for biochemical analysis of retroviral integration. Proc. Natl. Acad. Sci. USA 86:3065-3069.
9. Katzman, M., and M. Sudol. 1996. Influence of subterminal viral DNA nucleotides on differential susceptibility to cleavage by human immunodeficiency virus type 1 and visna virus integrases. J. Virol. 70:9069-9073.
10. Julias, J. G., M. J. McWilliams, S. G. Sarafianos, W. G. Alvord, E. Arnold, and S. H. Hughes. 2004. Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage. J. Virol. 78:13315-13324.
11. LaFemina, R. L., P. L. Callahan, and M. G. Cordingley. 1991. Substrate specificity of recombinant human immunodeficiency virus integrase protein. J. Virol. 65:5624-5630.
12. Leavitt, A. D., R. B. Rose, and H. E. Varmus. 1992. Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae. J. Virol. 66:2359-2368.
13. Masuda, T., M. J. Kuroda, and S. Harada. 1998. Specific and independent recognition of U3 and U5 att sites by human immunodeficiency virus type 1 integrase in vivo. 1998. J. Virol. 72:8396-8402.
14. McWilliams, M. J., J. G. Julias, S. G. Sarafianos, W. G. Alvord, E. Arnold, and S. H. Hughes. 2003. Mutations in the 5′ end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer. J. Virol. 77:11150-11157.
15. Powell, M. D., and J. G. Levin. 1996. Sequence and structural determinants required for priming of plus-strand DNA synthesis by the human immunodeficiency virus type 1 polypurine tract. J. Virol. 70:5288-5296.
16. Oh, J., K. W. Chang, and S. H. Hughes. 2006. Mutations in the U5 sequences adjacent to the primer binding site do not affect tRNA cleavage by Rous sarcoma virus RNase H but do cause aberrant integrations in vivo. J. Virol. 80:451-459.
17. Oh, J., K. W. Chang, W. G. Alvord, and S. H. Hughes. 2006. Alternate polypurine tracts affect Rous sarcoma virus integration in vivo. J. Virol. 80:10281-10284.
18. Oh, J., K. W. Chang, R. Wierzchoslawski, W. G. Alvord, and S. H. Hughes. 2008. Rous sarcoma virus (RSV) integration in vivo: a CA dinucleotide is not required in U3, and RSV linear DNA does not autointegrate. J. Virol. 82:503-512.
19. Reicin, A. S., G. Kaplana, S. Paik, S. Marmon, and S. Goff. 1995. Sequences in the human immunodeficiency virus type 1 U3 region required for in vivo and in vitro integration. J. Virol. 69:5904-5907.
20. Roth, M. C., P. L. Schwartzberg, and S. P. Goff. 1989. Structure of the termini of DNA intermediates in the integration of retroviral DNA: dependence on IN function and terminal DNA sequence. Cell 58:47-54.
21. Sherman, P. A., and J. A. Fyfe. 1990. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl. Acad. Sci. USA 87:5119-5123.
22. Vink, C., D. C. van Gent, Y. Elgersma, and R. H. Plasterk. 1991. Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. J. Virol. 65:4636-4644.
23. Vora, A., and D. P. Grandgenett. 2001. DNase protection analysis of retrovirus integrase at the viral DNA ends for full-site integration in vitro. 2001. J. Virol. 75:3556-3567.
24. Yoshinaga, T., and T. Fujiwara. 1995. Different roles of bases within the integration signal sequence of human immunodeficiency virus type 1 in vitro. J. Virol. 69:3233-3236.